Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The causative gene in cystic fibrosis (CF) was identified in 1989, 3 years before the publication of the first issue of Human Molecular Genetics. The cystic fibrosis transmembrane conductance regulator (CFTR) gene was among the first underlying a common inherited disorder to be cloned, and hence, its subsequent utilization toward a cure for CF provides a roadmap for other monogenic diseases. Over the past 30 years, the advances that built upon knowledge of the gene and the CFTR protein to develop effective therapeutics have been remarkable, and yet, the setbacks have also been challenging. Technological progress in other fields has often circumvented the barriers. This review focuses on key aspects of CF diagnostics and current approaches to develop new therapies for all CFTR mutations. It also highlights the major research advances that underpinned progress toward treatments and considers the remaining obstacles.

Original publication

DOI

10.1093/hmg/ddab191

Type

Journal article

Journal

Hum Mol Genet

Publication Date

01/10/2021

Volume

30

Pages

R264 - R273

Keywords

Animals, CRISPR-Cas Systems, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Disease Management, Gene Editing, Gene Expression Regulation, Genetic Association Studies, Genetic Predisposition to Disease, Genetic Therapy, Humans, Molecular Diagnostic Techniques, Mutation, Single-Cell Analysis